Scientists have identified a gene that slows the spread of pancreatic cancer tumours, paving the way for targeted treatment of one of the deadliest forms of the disease, said a paper published Sunday.
After discovering the gene dubbed USP9X at work in a study of pancreatic cancer in mice, the international research team found it also played a role in humans.
"We looked in human tumour specimens and we found that it was missing in a fraction of patients -- the patients that did very poorly ... the people who died the fastest," researcher David Tuveson told AFP.
"Patients that had a low level of the gene expressed ... they died very quickly after their operation and the patients who at the end of their life had lots of metastasis (spreading of the cancer), they had also a very low level of this protein."
The existence of the gene, which is found in all of our cells but goes missing in some tumours, was known before but not its role as a cancer suppressor, said Tuveson.
Three other pancreatic tumour suppressor genes are known to exist, but this is the one whose absence "probably causes metastasis -- that is what kills people with pancreas cancer," said the scientist.
The discovery means that "we can wake up the gene by using drugs" known as epigenetic modulators, he added.
"Our observation allows us to potentially treat people that have lost this gene in the pancreas tumours. It allows us to offer a therapy for the patients that actually have the worst prognosis."
Tuveson said these kinds of drugs have already been developed, "but people haven't figured out where exactly they would be useful.
"We are proposing that these drugs would be useful in this subset of pancreas cancer patients."
Pancreatic cancer kills about 96 percent of its victims within five years of diagnosis, one of the lowest cancer survival rates.
Early diagnosis is difficult, so the disease is often discovered only after it has already spread.
Explore further: Gene identified in increasing pancreatic cancer risk